21149 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
ACTIVATION OF RESIDENT MEMORY T CELLS FOR THE TREATMENT OF CANCER
#2COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TRANSPLANT REJECTION
#3Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#4AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
#5INTERLEUKIN 15 VARIANTS
#6CONDITIONING FOR IN VIVO IMMUNE CELL ENGINEERING
#7COMBINATION THERAPIES COMPRISING T-CELL REDIRECTING THERAPIES AND AGONISTIC ANTI-IL-2R ANTIBODIES OR FRAGMENTS THEREOF
#8USE OF NKG2D-BASED CELL ADAPTER MOLECULE IN REMOVAL OF AGING CELLS
#9ANTI-CCR8 ANTIBODIES AND USES THEREOF
#10METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY
#11COMBINATION CONTAINING AN MRNA VACCINE OR AN MRNA ENCODED THERAPEUTIC PROTEIN AND AN IMMUNE MODULATING MRNA FOR IMPROVED OR REDUCED IMMUNOGENICITY TO INCREASE EFFICACY
#12BACTERIAL COMPOSITIONS AND METHODS OF USE
#13IDENTIFICATION OF HIGHLY IMMUNOSUPRESIVE TREG POPULATION IN TUMOR MICROENVIRONMENTS
#14COMBINATION TUMOR IMMUNOTHERAPY
#15Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
#16METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
#17COMBINATIONS OF CTLA4 BINDING PROTEINS AND METHODS OF TREATING CANCER
#18ANTI-CTLA4 ANTIBODIES FOR TREATMENT OF KRAS MUTANT CANCERS
#19IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#20NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#21USES AND METHODS FOR IL-2, IL-13, AND IL-4 CYTOKINE BIFUNCTIONAL MOLECULES
#22USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER
#23METHODS FOR TREATING LUPUS NEPHRITIS USING FCRN ANTAGONISTS
#24COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
#25COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES
#26COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN BINDING MOLECULES
#27ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
#28HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
#29METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS
#30VIRAL DELIVERY OF NEOANTIGENS
#31COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY
#32METHODS FOR TREATING MULTIPLE MYELOMA
#33COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
#34NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION
#35Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#36Compositions For and Methods of Preventing Metastases
#37IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
#38CHIMERIC ANTIGEN RECEPTOR TUMOR INFILTRATING LYMPHOCYTES
#39FCRN ANTAGONISTS WITH IMPROVED HALF-LIFE AND METHODS OF USE
#40METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING CD19T AND BISPECIFIC T CELL ENGAGERS
#41COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASES
#42NOVEL VACCINES AGAINST HPV AND HPV-RELATED DISEASES
#43AGONISTIC ANTIBODIES THAT BIND CD40
#44PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF
#45MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF
#46METHOD FOR HIGH THROUGHPUT PEPTIDE-MHC AFFINITY SCREENING FOR TCR LIGANDS
#47ANTI-EGFR/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF
#48HER2-TARGETING ANTIGEN BINDING MOLECULES COMPRISING 4-1BBL
#49METHODS FOR TREATING MULTIPLE MYELOMA
#50METHOD OF TREATING CANCER USING A COMBINATION OF ENTINOSTAT AND AN ANTI-CSF-1R ANTIBODY
#51ANTI-TIGIT ANTIBODIES
#52METHODS AND MATERIALS FOR TREATING CANCER
#53ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
#54COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS
#55METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#56HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
#57METHODS FOR TREATING MULTIPLE MYELOMA
#58COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE
#59Combination Treatment
#60COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#61MODIFIED PARAMYXOVIRIDAE ATTACHMENT GLYCOPROTEINS
#62METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES
#63COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
#64INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSE
#65ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
#66METHODS OF INDUCING ORGAN TRANSPLANTATION IMMUNE TOLERANCE AND ASSOCIATED COMPOSITIONS AND METHODS
#67ANTI-CD25 ANTIBODY AGENTS
#68COMPOSITIONS AND METHODS OF ENHANCING ANTI-TUMOR RESPONSE USING HYBRID NEUTROPHILS
#69Compositions and Methods for Identifying and Modulating Metabolic Health
#70TRANSPLANT MATERIAL AND KIDNEY TRANSPLANT KIT
#71METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
#72COMBINATION CANCER THERAPY
#73Anti-CCR8 Antibodies and Uses Thereof
#74Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
#75MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#76THERAPEUTIC COMBINATION FOR TREATING CANCER
#77PARATHYROID HORMONE RECEPTOR 1(PTH1R) ANTIBODIES AND USES THEREOF
#78ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
#79INFLAMMASOME ANTIBODY COMPOSITON AND METHOD FOR TREATING NEUROLOGIC DISORDER
#80METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
#81ANTIBODIES TO TIGIT
#82METHODS AND COMPOSITIONS FOR ENHANCING THE POTENCY OF SUPERANTIGEN MEDIATED CANCER IMMUNOTHERAPY
#83METHODS OF TREATING HEMATOLOGIC CANCERS
#84USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER
#85ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
#86VIRAL DELIVERY OF NEOANTIGENS
#87EP4 INHIBITORS AND USE THEREOF
#88Vaccines against HPV and HPV-related diseases
#89METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES
#90PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
#91De-immunized factor VIII molecule and pharmaceutical compositions comprising the same
#92APPROACH FOR TREATMENT OF CANCER VIA IMMUNOMODULATION BY USING TALABOSTAT
#93Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#94REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPY
#95Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#96Anti-CD3 antibodies and uses thereof
#97MYELIN OLIGODENDROCYTE GLYCOPROTEIN-SPECIFIC PEPTIDE FOR THE TREATMENT OR PREVENTION OF MULTIPLE SCLEROSIS
#98COMPOUNDS AND METHODS FOR TREATING CANCER
#99ANTIGEN BINDING PROTEINS
#100FLT3 LIGAND FUSION PROTEINS AND METHODS OF USE
#101ANTIBODY FORMULATIONS
#102ANTIGEN BINDING PROTEINS
#103METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
#104Compositions and methods for the removal of biofilms
#105GENE EDITING METHODS AND COMPOSITIONS FOR ELIMINATING RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY
#106METHODS OF TREATING SKIN CANCER BY ADMINISTERING A PD-1 INHIBITOR
#107SELF-ASSEMBLING PRODRUGS AS IMMUNE BOOSTERS FOR CANCER IMMUNOTHERAPY
#108TREATMENT WITH ANTI-VEGF ANTIBODIES
#109BINDING MOLECULES WITH MODIFIED J-CHAIN
#110Polyspecific Binding Molecules and their use in Cell Therapy
#111Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels
#112METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY
#113Anti-TIGIT Antibodies
#114Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
#115Anti-TIGIT Antibodies
#116COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY
#117METHODS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DEPOSITION DISEASES
#118PD1-BASED VACCINATION COMPOSITION AND METHODS THEREOF
#119Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
#120Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
#121METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
#122IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#123ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES
#124METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
#125ANTI-GITR ANTIBODIES AND USES THEREOF
#126COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#127ANTICANCER COMBINATION THERAPY
#128COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
#129COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
#130TREATMENT OF NEUROINFLAMMATORY DISEASE
#131COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1
#132INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
#133ANTIBODY AGAINST SUPER-REPRESSOR IkB AND USE THEREOF
#134Combined organ and hematopoietic cells for transplantation tolerance of grafts
#135ANTI CANCER COMBINATION THERAPY
#136HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74
#137USE OF HIGH-AFFINITY, LIGAND-BLOCKING, HUMANIZED ANTI-T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN-3 (TIM-3) IGG4 ANTIBODY FOR THE TREATMENT OF MYELOFIBROSIS
#138FLT3 ligand fusion proteins and methods of use
#139THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B
#140COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#141CD80 and CD86 Binding Protein Compositions and Uses Thereof
#142CD80 and CD86 binding protein compositions and uses thereof
#143CD200R AGONIST ANTIBODIES AND USES THEREOF
#144METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS
#145IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
#146MONOCLONAL ANTIBODY AND A METHOD OF USE FOR THE TREATMENT OF LUPUS
#147Bispecific and monospecific antibodies using novel anti-PD-1 sequences
#148Compositions and methods for the removal of biofilms
#149BINDING MOLECULES BINDING PD-L1 AND LAG-3
#150Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#151Methods and Compositions for Treating Melanoma
#152RECOMBINANT PROTEINS WITH CD40 ACTIVATING PROPERTIES
#153Methods of sensitizing cancer to immunotherapy
#154METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
#155COMPOSITIONS AND METHODS OF TREATING CANCER
#156Modulation of molecular markers using S-equol
#157Kit comprising contiguous nucleobases, including position 76, of RS5745994
#158Methods and compositions for treating virus-associated inflammation
#159ANTI-CD40 ANTIBODIES AND USES THEREOF
#160COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE
#161TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM
#162METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE
#163METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS
#164Prevention or mitigation of T-cell bispecific antibody-related adverse effects
#165Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies
#166NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENT
#167BIHAPTENIZED AUTOLOGOUS VACCINES AND USES THEREOF
#168USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY
#169METHODS OF TREATING HEMATOLOGIC CANCERS
#170ErbB2 SIGNALING AND NERVE REGENERATION
#171Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
#172Humanized anti-CD79B antibodies and immunoconjugates and methods of use
#173Anti-PD-L1 antibodies and methods of making and using thereof
#174BI-SPECIFIC CONJUGATES
#175TRANSDERMAL SYSTEM FOR SYNERGISTIC IMMUNE-CHEMOTHERAPY USING MICRONEEDLES AND METHOD OF TREATMENT THEREOF
#176INDUCED STEM MEMORY T CELLS AND METHODS OF USE THEREOF
#177Antigen binding proteins that bind PD-L1
#178Dosage regimen for MAdCAM antagonists
#179METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
#180PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
#181High-concentration monoclonal antibody formulations
#182EP4 INHIBITORS AND USE THEREOF
#183COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME RELATED DISEASES OR CONDITIONS
#184Compositions and methods for identifying and modulating metabolic health
#185RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
#186BISPECIFIC ANTIBODY AND USE THEREOF
#187Vaccines against HPV and HPV-related diseases
#188Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
#189NOVEL BISPECIFIC AGONISTIC 4-1BB ANTIGEN BINDING MOLECULES
#190GM-CSF/CD40L VACCINE AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#191DRUG DELIVERY COMPOSITIONS AND USES THEREOF
#192CHIMERIC ANTIGEN RECEPTOR TUMOR INFILTRATING LYMPHOCYTES
#193Polypeptides
#194COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME
#195Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
#196COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT
#197Composition for blocking angiogenesis
#198Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
#199Antibody binding TIM-3 and use thereof
#200CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER
#201Combined organ and hematopoietic cells for transplantation tolerance of grafts
#202Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
#203Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
#204NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#205ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
#206Anti-CD27 antibodies and uses thereof
#207COMPOSITIONS AND METHODS FOR THE IMMUNE CHECKPOINT BLOCKADE OF TIM4
#208Compositions and methods for CD20 immunotherapy
#209Anti-GITR antibodies and uses thereof
#210AGONISTIC ANTIBODIES THAT BIND CD40
#211PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD
#212Treating or preventing adverse liver conditions
#213A pharmaceutical combination for use in the treatment of cancer
#214COMBINATION THERAPY TO TREAT BRAIN CANCER
#215Engineered immune cells resistant to tumor microenvironment
#216Anti-PD-L1 antibodies and use thereof
#217COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF
#218COMBINATION THERAPY WITH TARGETED TGF-B INHIBITION FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
#219Human monoclonal antibodies against LAG3 and uses thereof
#220INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSE
#221COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT
#222Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
#223METHODS OF TREATING TUMOR
#224PRESENTING CELL AND USE THEREOF IN CELL THERAPY
#225BIORESPONSIVE HYDROGEL MATRIXES AND METHODS OF USE
#226Anti-CD39 antibody compositions and methods
#227ANTIBODIES BINDING PD-1 AND USES THEREOF
#228Antibodies and variants thereof against TIGIT
#229Anti-CEACAM antibodies and uses thereof
#230Combination therapy with targeted 4-1BB (CD137) agonists
#231ACTIVATION OF RESIDENT MEMORY T CELLS FOR THE TREATMENT OF CANCER
#232Methods and materials for treating cancer
#233COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES
#234C-MET agonistic antibody and use thereof
#235Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
#236Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer
#237Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
#238COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
#239Method of treating lower back pain
#240ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
#241Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
#242Anti-CD25 antibody agents
#243Anti-CD47 antibodies and uses thereof
#244Anti-CD25 for tumour specific cell depletion
#245Canine antibody therapeutic for treating cancer
#246METHODS FOR TREATING CANCER WITH ANTI PD-1 ANTIBODIES AND ANTI CTLA4 ANTIBODIES
#247METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES
#248Anti-CD25 for tumour specific cell depletion
#249IMMUNOMONOTHERAPY FOR UROTHELIAL CARCINOMA
#250METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
#251Anti-PD-1 antibodies
#252Anti-EGFR/anti-4-1BB bispecific antibody
#253HER2-targeting antigen binding molecules comprising 4-1BBL
#254METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION
#255Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
#256TREATMENT WITH ANTI-VEGF ANTIBODIES
#257Combination comprising immunostimulatory oligonucleotides
#258Anti-CD39 antibodies
#259Anti-CD25 for tumour specific cell depletion
#260Anti-CD25 for tumour specific cell depletion
#261Anti-CD25 for tumour specific cell depletion
#262Anti-CD25 antibody agents
#263ANTI-VEGFR-2 ANTIBODY
#264BISPECIFIC ANTIBODIES TO TNF-ALPHA AND IL-1BETA AND USES THEREOF
#265IMPROVING ANTI-PD-1 CANCER THERAPY
#266Multi-valent hepatitis B virus antigen binding molecules and uses thereof
#267Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#268COMBINATION THERAPIES
#269METHODS AND COMPOSITIONS FOR MODULATING THYMIC FUNCTION
#270Anti-CD25 antibody agents
#271ANTI-TIGIT ANTIBODIES
#272Fusion Proteins Containing CD48 Antibodies and Cytokines
#273BISPECIFIC ANTIBODIES TO MOSPD2 AND T CELL- OR NK CELL-SPECIFIC MOLECULES
#274HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE
#275INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
#276UNIVERSAL ANTIGEN PRESENTING CELLS AND USES THEREOF
#277USE OF BISPECIFIC ANTIBODY AND IL-15 FOR COMBINATION THERAPY
#278Reducing beta-catenin expression to potentiate immunotherapy
#279Agonistic antibodies that bind human CD40 and uses thereof
#280BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
#281Methods for depleting or inhibiting the migration of regulatory T-cells in early or late stages of cancer
#282Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
#283IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
#284Combination Treatment
#285ANTIBODIES TO OPGL
#286Bispecific molecules comprising an HIV-1 envelope targeting arm
#287Methods for treating lung inflammation with an anti-ASC antibody
#288Compositions and methods of treatment of Ehlers-Danlos syndromes
#289T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
#290Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
#291METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS
#292Antibodies to TIGIT
#293Composition to induce bone marrow stem cell mobilization
#294COMBINATION TUMOR IMMUNOTHERAPY
#295CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
#296Anti-TIGIT antibodies
#297ANTI-CD40 ANTIBODIES AND USES THEREOF
#298Binding molecules with modified J-chain
#299Combined organ and hematopoietic cells for transplantation tolerance of HLA mismatched grafts
#300Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels